Analysts expect Natera Inc (NASDAQ:NTRA) to announce sales of $56.83 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Natera’s earnings. The lowest sales estimate is $56.00 million and the highest is $57.66 million. Natera reported sales of $49.30 million during the same quarter last year, which indicates a positive year over year growth rate of 15.3%. The company is scheduled to report its next earnings report on Tuesday, March 6th.

According to Zacks, analysts expect that Natera will report full-year sales of $56.83 million for the current fiscal year, with estimates ranging from $213.10 million to $222.40 million. For the next fiscal year, analysts anticipate that the business will post sales of $262.75 million per share, with estimates ranging from $237.80 million to $287.10 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Natera.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The business had revenue of $56.66 million for the quarter, compared to analyst estimates of $55.31 million. Natera had a negative net margin of 62.34% and a negative return on equity of 197.09%. The company’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the firm earned ($0.50) earnings per share.

NTRA has been the topic of a number of recent research reports. Zacks Investment Research raised shares of Natera from a “sell” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Wednesday, October 11th. Robert W. Baird reaffirmed a “buy” rating on shares of Natera in a research report on Tuesday, October 24th. Morgan Stanley reaffirmed an “overweight” rating and set a $16.00 price target (up from $13.00) on shares of Natera in a research report on Friday, October 6th. Canaccord Genuity reaffirmed a “buy” rating and set a $15.00 price target on shares of Natera in a research report on Tuesday, November 14th. Finally, Cowen reaffirmed a “buy” rating and set a $12.00 price target on shares of Natera in a research report on Thursday, December 21st. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $14.50.

Shares of Natera (NASDAQ:NTRA) traded down $0.38 during mid-day trading on Friday, reaching $8.99. 113,921 shares of the company’s stock were exchanged, compared to its average volume of 99,193. The company has a debt-to-equity ratio of 2.43, a quick ratio of 1.75 and a current ratio of 1.85. Natera has a 1 year low of $7.35 and a 1 year high of $14.76.

Institutional investors and hedge funds have recently bought and sold shares of the company. Virtu KCG Holdings LLC purchased a new stake in shares of Natera during the second quarter valued at approximately $126,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Natera during the second quarter valued at approximately $151,000. Voya Investment Management LLC raised its stake in shares of Natera by 17.8% during the second quarter. Voya Investment Management LLC now owns 14,663 shares of the medical research company’s stock valued at $159,000 after purchasing an additional 2,212 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Natera during the third quarter valued at approximately $171,000. Finally, Wells Fargo & Company MN raised its stake in shares of Natera by 2.8% during the second quarter. Wells Fargo & Company MN now owns 18,031 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 491 shares during the period. Institutional investors own 66.06% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Natera Inc (NTRA) Expected to Post Quarterly Sales of $56.83 Million” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/31/natera-inc-ntra-expected-to-post-quarterly-sales-of-56-83-million.html.

About Natera

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related stocks with our FREE daily email newsletter.